-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Edaravone in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Edaravone in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Edaravone in Amyotrophic Lateral Sclerosis Drug Details:Edaravone is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fosgonimeton in Lewy Body Dementia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fosgonimeton in Lewy Body Dementia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Fosgonimeton in Lewy Body DementiaDrug Details:Fosgonimeton is under development for the treatment...
-
Company Insights
Innovation and Patenting activity of Shattuck Labs Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shattuck Labs Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Shattuck Labs Inc – Company Profile
Shattuck Labs Inc (Shattuck) is a biotechnology company that develops bi-functional fusion proteins for the treatment of cancer and autoimmune disease. The company develops products using its proprietary agonist redirected checkpoint (ARC) platform and gamma delta T Cell engager (GADLEN) platform. Shattuck’s lead products include, SL-172154 (SIRPα-Fc-CD40L) developed for the treatment of ovarian cancer, cutaneous squamous-cell carcinoma (cSCC) and head and neck squamous cell carcinoma (HNSCC) and SL-279252 (PD1-Fc-OX40L) for advanced solid tumors and lymphoma. The company is also evaluating...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Products Market Report Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss...
-
Product Insights
Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Kidney Cancer Pipeline Products Market Report Overview Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, anemia, shortness of breath, and bone pain. Treatment includes surgery, radiation therapy, and chemotherapy. The kidney cancer pipeline market research report provides comprehensive information on the therapeutics under development for kidney cancer, complete with...
-
Product Insights
Melanoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. The Melanoma pipeline market research report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. The condition rarely causes signs or symptoms in the early stages of the disease. The symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding, and frequent infections. The Myelodysplastic Syndrome pipeline market research report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SL-279252
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SL-279252 Drug Details SL-279252 (TAK-252) is under development for the treatment of squamous non-small...